X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8) 8
multiple myeloma (8) 8
humans (6) 6
hematology, oncology and palliative medicine (5) 5
multiple myeloma - drug therapy (5) 5
oncology (5) 5
abridged index medicus (3) 3
aged (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
bortezomib (3) 3
care and treatment (3) 3
diagnosis (3) 3
female (3) 3
hematology (3) 3
male (3) 3
product development (3) 3
proteins (3) 3
survival (3) 3
therapy (3) 3
transplants & implants (3) 3
adult (2) 2
analysis (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
autografts (2) 2
bone marrow (2) 2
bone-marrow (2) 2
chemotherapy (2) 2
clinical trials (2) 2
corticosteroids (2) 2
dexamethasone (2) 2
drug administration schedule (2) 2
drug dosages (2) 2
drug therapy (2) 2
drugs (2) 2
kaplan-meier estimate (2) 2
lenalidomide plus dexamethasone (2) 2
medicine, general & internal (2) 2
middle aged (2) 2
multicenter (2) 2
multiparameter flow-cytometry (2) 2
multiple myeloma - diagnosis (2) 2
multiple myeloma - pathology (2) 2
patients (2) 2
plasma (2) 2
positron-emission-tomography (2) 2
prednisone (2) 2
prognosis (2) 2
randomization (2) 2
risk factors (2) 2
spain (2) 2
stem cell transplantation (2) 2
stem cells (2) 2
stem-cell transplantation (2) 2
steroids (2) 2
studies (2) 2
thalidomide (2) 2
thalidomide - administration & dosage (2) 2
transplantation (2) 2
treatment outcome (2) 2
urine (2) 2
acid combination therapy (1) 1
adults (1) 1
age factors (1) 1
aged patients (1) 1
aged, 80 and over (1) 1
anemia (1) 1
angiogenesis inhibitors (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antigens, surface - drug effects (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents, alkylating - administration & dosage (1) 1
antitumor-activity (1) 1
apoptosis (1) 1
apoptosis - drug effects (1) 1
arsenic trioxide (1) 1
arsenicals - pharmacology (1) 1
asthma (1) 1
binding sites (1) 1
biological products (1) 1
biomarkers (1) 1
biomarkers, tumor (1) 1
biopsy (1) 1
bone cancer (1) 1
bone marrow cells (1) 1
bone marrow cells - pathology (1) 1
boronic acids - administration & dosage (1) 1
canada (1) 1
carfilzomib (1) 1
case-control studies (1) 1
cd38 antigen (1) 1
cell cycle - drug effects (1) 1
cell survival (1) 1
cell-proliferation (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs.... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Refractory materials | Inhibitors | Interactive systems | Response rates
Journal Article
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Journal Article
Lancet (London, England), ISSN 0140-6736, 01/2020, Volume 395, Issue 10218, pp. 132 - 141
Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous... 
Corticosteroids | Bortezomib | Patient outcomes | Analysis | Multiple myeloma | Product development | Prednisone
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 12, pp. 1157 - 1165
Summary The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide,... 
Hematology, Oncology and Palliative Medicine | APOPTOSIS | IN-VITRO | ONCOLOGY | BONE-MARROW | ACID COMBINATION THERAPY | CELL-PROLIFERATION | KAPPA-B PATHWAY | PROTEASOME INHIBITOR | ANTITUMOR-ACTIVITY | HEMATOLOGIC MALIGNANCIES | ARSENIC TRIOXIDE | Apoptosis - drug effects | Humans | Heat-Shock Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Depsipeptides - pharmacology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Multiple Myeloma - drug therapy | Receptors, Cell Surface - drug effects | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Multiple Myeloma - physiopathology | NF-kappa B - antagonists & inhibitors | Protein Kinases - drug effects | Antibodies, Monoclonal - pharmacology | Arsenicals - pharmacology | Enzyme Inhibitors - pharmacology | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - drug effects | Oxides - pharmacology | Signal Transduction - drug effects | Farnesyl-Diphosphate Farnesyltransferase - antagonists & inhibitors | Cysteine Proteinase Inhibitors - pharmacology | Histone Deacetylase Inhibitors | TOR Serine-Threonine Kinases | Cell Cycle - drug effects | Oligopeptides - pharmacology | Antigens, Surface - drug effects | DNA Methylation - drug effects | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Drugs | Medical research | Multiple myeloma | Clinical trials | Medicine, Experimental | Drug therapy | Drug approval
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.